President and CEO Ibraheem “Ibs” Mahmood is cited in Editor-in-Chief Taren Grom’s Letter from the Editor and in the thought-provoking article: C-Suite Outlook: Leading Through Extraordinary Change
Important Cookie Information – This message will only appear once.
DrugDev websites use cookies. By continuing to browse the site you are agreeing to our use of cookies. For more details about cookies and their use, please see our Privacy Policy.
